ResMed (RMD) is expected to report Q2 earnings after market close Thursday, February 5 with a conference call scheduled for 4:30 pm ET.
Analysts are looking for a profit of 42c on revenue of $222M. The consensus is 38c-44c for EPS, and revenue of $208.7M-$229.2M, according to First Call. The company reported Q1 EPS 36c vs. consensus of 38c and Q1 revenue $217.9M vs. consensus of $217.45M. The positives for this quarter's results will come from the company's newer products like the Mirage Micro nasal mask. International sales are also expected to contribute to the top line. Results from this quarter might be impaired by currency headwinds brought on by the strengthening dollar.
On January 20, Wachovia said ResMed should be able to overcome the economic slowdown. Wachovia maintained an Outperform rating on the stock.